**Metabolomic consequences of genetic inhibition of PCSK9**

**compared with statin treatment**

Sliz *et al*, Metabolomic consequences of PCSK9 inhibition and statins

**Address for Correspondence**:

Peter Würtz, Nightingale Health Ltd, Mannerheimintie 164a, 00300 Helsinki, Finland;

peter.wurtz@nightingalehealth.com; Phone: +358 504670900

**Word count**: 4250

# ABSTRACT

**Background:** Both statins and PCSK9 inhibitors lower blood low-density lipoprotein cholesterol (LDL‑C) levels to reduce risk of cardiovascular events. To assess potential differences between metabolic effects of these two lipid-lowering therapies, we performed detailed lipid and metabolite profiling ­of a large randomized statin trial and compared the results with the effects of genetic inhibition of PCSK9, acting as a naturally occurring trial.

**Methods:** 228 circulating metabolic measures were quantified by nuclear magnetic resonance spectroscopy, including lipoprotein subclass concentrations and their lipid composition, fatty acids, and amino acids, for 5,359 individuals (2,659 on treatment) in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) trial at 6-months post-randomization. The corresponding metabolic measures were analyzed in eight population cohorts (N=72,185) using *PCSK9* rs11591147 as an unconfounded proxy to mimic the therapeutic effects of PCSK9 inhibitors.

**Results:** Scaled to an equivalent lowering of LDL-C, the effects of genetic inhibition of PCSK9 on 228 metabolic markers were generally consistent with those of statin therapy (*R*2=0.88). Alterations in lipoprotein lipid composition and fatty acid distribution were similar. However, discrepancies were observed for very-low-density lipoprotein (VLDL) lipid measures. For instance, genetic inhibition of PCSK9 had weaker effects on lowering of VLDL-cholesterol compared with statin therapy (54% vs. 77% reduction, relative to the lowering effect on LDL-C; *P*=2x10-7 for heterogeneity). Genetic inhibition of PCSK9 showed no significant effects on amino acids, ketones, or a marker of inflammation (GlycA) whereas statin treatment weakly lowered GlycA levels.

**Conclusions:** Genetic inhibition of PCSK9 had similar metabolic effects to statin therapy on detailed lipid and metabolite profiles. However, PCSK9 inhibitors are predicted to have weaker effects on VLDL lipids compared with statins for an equivalent lowering of LDL-C, which potentially translate into smaller reductions in cardiovascular disease risk.

**Keywords:** metabolic profiling — cholesterol lowering — Mendelian randomization — lipoproteins — drug development

# CLINICAL PERSPECTIVE

1. What is new?
* Detailed lipoprotein lipid and metabolic effects of statin therapy in a large randomized controlled trial are compared with the corresponding effects of PCSK9 genetic inhibition in large population studies, acting as a naturally occurring trial of PCSK9 inhibitors.
* We demonstrate generally consistent effects of statins and PCSK9 genetic inhibition on a wide range of lipid-related metabolic markers when scaled to a similar lowering of LDL-C.
* Differences are observed in lowering of VLDL lipids and, more subtly, for the inflammation marker GlycA, with PCSK9 inhibition appearing to have a weaker effect as compared to statins.
1. What are the clinical implications?
* If VLDL lipids have independent causal effects on cardiovascular disease risk, the observed discrepancy on VLDL lipid lowering could contribute to differences in cardiovascular risk reductions between statins and PCSK9 inhibitors for an equivalent reduction in LDL-C.
* The null associations on glycolysis related measures and amino acids suggests that alternative mechanisms account for the association of genetic variants in *PCSK9* and risk of type 2 diabetes.
* These results exemplify the utility of large-scale metabolomic profiling with genetics and randomized trial data to uncover potential molecular differences between related therapeutics.

# INTRODUCTION

Statins are first line therapy to lower blood levels of low-density lipoprotein cholesterol (LDL-C) and reduce the risk of cardiovascular events (1-3). Treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has emerged as an additional effective therapy to lower LDL-C, resulting in reductions of approximately 45–60% (4,5). Large cardiovascular outcome trials have recently demonstrated that PCSK9 inhibitors reduce the risk of major cardiovascular events when added to statin treatment (6,7). Based on the first major outcome trials (6), there has been some suggestions that PCSK9 inhibitors may be slightly less efficacious than statins for equivalent LDL-C reductions; however, other reports suggest that this is not the case, with apparent differences in cardiovascular event reduction explained by the short duration of the PCSK9 trials (8). Assessment of the detailed lipoprotein and other metabolic effects of statins and PCSK9 inhibitors could provide a more detailed understanding of these lipid-lowering therapies and shed light on potential differential effects on lipid metabolism.

The anticipated pharmacological effects of PCSK9 inhibitors may be assessed by LDL-C lowering alleles in the *PCSK9* gene, which act as unconfounded proxies for the lifetime effects of treatments (9-11). The observation of a prominent lower risk of coronary heart disease with LDL-C loweringalleles in *PCSK9* was pivotalfor accelerating the development of anti-PCSK9 therapeutics (10). Supporting the validity of using genetic proxies for molecular characterization of lipid-lowering targets, we have previously shown that LDL-C lowering alleles in *HMGCR* (the gene encoding the target for statins) closely recapitulate the detailed metabolic changes associated with starting statin therapy in longitudinal cohorts, as assessed by nuclear magnetic resonance (NMR) metabolomics (12). These detailed metabolic effects of statins were recently confirmed in PREVEND IT (Prevention of Renal and Vascular End-stage Disease Intervention Trial), a small randomized trial (13). Other studies have assessed the associations of *PCSK9* variantswith lipoprotein subclass profiles (14,15), and the treatment effects of PCSK9 inhibitors on lipoprotein particle concentrations and lipidomic measures have been examined in several small trials (16-18). However, prior studies have had limited power to assess potential differences between PCSK9 inhibition and statin therapy for equivalent reductions in LDL-C, complicating direct comparisons of their impact on detailed lipid and metabolite measures.

In the present study, we examined the effects of statin therapy and genetic inhibition of PCSK9 on a circulating profile of 228 metabolic measures, quantified by NMR metabolomics, including lipoprotein subclasses, their lipid concentrations and composition, fatty acid balance, and several non-lipid pathways. The metabolic effects of statin treatment were assessed in a large randomized placebo-controlled trial. In the absence of NMR metabolomics data from a large randomized trial of PCSK9 inhibitor therapy, the anticipated pharmacological effects were examined for a loss-of-function variant in the *PCSK9* gene (10,19). Comparing the metabolomic effects of genetic inhibition of PCSK9 to statin therapy provides an opportunity to examine possible discrepancies in many circulating biomarkers, and in turn elucidate potential therapeutic differences in the molecular mechanisms to reduce cardiovascular risk.

# METHODS

## The authors declare that the summary statistics are available within the article and its online supplementary files. The individual patient data analyzed in this study are available by application to the respective cohort committees.

## Study design

An overview of the study design is shown in **Figure 1**. NMR metabolomics was performed on 5,359 blood samples from the PROSPER (PROspective Study of Pravastatin in the Elderly at Risk) trial (20) at 6-month post-randomization, and 72,185 samples from eight population cohorts from the United Kingdom (INTERVAL (21), Avon Longitudinal Study of Parents (ALSPAC) mothers and offspring (22,23)), Finland (FINRISK-1997, FINRISK-2007, and Northern Finland Birth Cohort studies 1966 and 1986 (24-26)), and China (China Kadoorie Biobank (27)). All study participants provided written informed consent, and study protocols were approved by the local ethics committees.

PROSPER is a double-blind, randomized placebo-controlled trial investigating the benefit of pravastatin (40 mg/day) in elderly individuals at risk of cardiovascular disease, with 5,804 participants (70–82 years old) from Scotland, Ireland and the Netherlands enrolled between December 1997 and May 1999 (28). All participants had above average plasma total cholesterol concentration (4.0 to 9.0 mmol/L) at baseline and 50% had prior vascular disease. For the present study, 5,359 samples (2,659 on pravastatin) were measured by NMR metabolomics; all were previously unthawed 6-month post-randomization EDTA plasma samples stored at -80°C (28). Metabolite data from baseline samples were not available, however the randomization should ensure that there are limited between-group differences at baseline. Replication of the metabolic effects of pravastatin in PROSPER was done by comparison with recent results from PREVEND-IT (13).

The metabolic effects of PCSK9 inhibition were assessed via the principle of Mendelian randomization using rs11591147-T (R46L), a loss-of-function allele robustly associated with lower LDL-C and decreased cardiovascular risk (10,11). The frequency of carriers of this effect allele was 2.2% (N=3,135 carriers); clinical characteristics of these individuals are specified in **Table S1.** Additional genetic variants in the *PCSK9* locus, which have previously been used in Mendelian randomization studies on *PCSK9* (11,29), and display low linkage disequilibrium with rs11591147 (*R*2<0.2), were assessed in sensitivity analyses. To complement the comparison of *PCSK9* rs11591147-T effects against the statin trial, we further examined the metabolic effects of rs12916-T­ in *HMGCR* inthe same study population*,* acting as a ‘pseudo-trial’ of a very small statin dose bynaturally occurring randomization of HMG-CoA reductase inhibition (12,30). Among SNPs in *HMGCR*, rs12916­ exhibits the strongest association with LDL-C and has been shown to affect hepatic *HMGCR* expression as well as cardiovascular risk (11,12,30). Finally, to corroborate the validity of using genetic proxies to mimic the randomized trial effects, we compared metabolic effects of statin treatment in PROSPER with the corresponding effects of *HMGCR* rs12916-T. Pregnant women and individuals on lipid-lowering treatment were excluded from the analyses where information was available. Details of the cohorts are provided in **Supplementary Methods** and **Supplementary Table 1**.

## Lipid and metabolite quantification

High-throughput NMR metabolomics was used to quantify 228 lipoprotein lipids and polar metabolite measures from serum or plasma samples in the PROSPER trial and eight cohorts by the Nightingale platform (Nightingale Health Ltd, Helsinki, Finland). This provides simultaneous quantification of routine lipids, particle concentration and lipid composition of 14 lipoprotein subclasses, abundant fatty acids, amino acids, ketones and glycolysis related metabolites in absolute concentration units (**Supplementary** **Table 2**) (31). The Nightingale NMR metabolomics platform has been widely used in epidemiological studies (12,32,33) and the measurement method has been previously described (31-35).

## Statistical analyses

The effects of statin therapy on the 228 metabolic measures in the PROSPER trial were assessed by comparing the mean metabolite concentrations in the treatment group with the placebo group at 6 months after randomization. The between-group difference in concentrations for each metabolic measure was quantified separately using linear regression with metabolite concentration as outcome and treatment status as predictor, adjusted for age and sex. All metabolite concentrations were scaled to standard deviation (SD) units prior to assessing the differences, to enable comparison of measures with different units and across wide ranges of concentration levels. Results in absolute units are presented in **Supplementary** **Table 3**. The percentage differences in metabolite concentrations, relative to the placebo group, were examined as secondary analyses.

The effect of genetic inhibition of PCSK9 on each of the 228 metabolic measures was analyzed separately by fitting linear regression models with metabolite concentrations as outcome and rs11591147-T allele count as predictor, representing the number of LDL-C lowering alleles. For sensitivity analysis, we conducted equivalent tests of each metabolic measure with rs12916­-T in *HMGCR* as the predictor*.* All genetic analyses assumed an additive effect and were adjusted for age, sex, and the first four genomic principal components. Effect sizes and standard errors from each cohort were combined using inverse variance-weighted fixed effect meta-analysis. All effect sizes were scaled to SD units of metabolite concentrations, as for analyses of PROSPER. The similarity between the overall patterns of metabolic effects due to PCSK9 inhibition and statin therapy was summarized using the linear fit of the effect estimates of 153 metabolic measures (12), covering all assayed measures except lipoprotein lipid ratios and five polar metabolites that could not be reliably quantified in PROSPER.

To facilitate comparison between the substantial metabolic effects of statin therapy with the smaller effects from genetic inhibition of PCSK9, results are presented relative to an equivalent (1-SD) lowering of LDL-C within each study design (as quantified by NMR metabolomics) (12,35). For the statin trial, the estimates derived from comparing statin treatment to placebo were divided by 1.19 (since statins lowered LDL-C by 1.19 SD); for PCSK9 genetic associations, per-allele effect estimates were divided by 0.44; for sensitivity analyses using rs12916 in *HMGCR*, per-allele effect estimates were divided by 0.078. The scaling relative to LDL-C was used to interpret the reported effect sizes as a change in concentration in each metabolic measure (in SD units) that accompanies a 1-SD lowering of LDL-C by statin therapy and genetic inhibition of PCSK9. This scaling is in line with the principles of Mendelian randomization assuming that the genetic variants in *PCSK9* and *HMGCR* serve as instruments for the LDL-C exposure.

Although 228 metabolic measures in total were examined, the number of independent tests performed is lower due to the correlated nature of the measures (35). The number of independent tests was estimated by taking the number of principal components explaining 99% of the variation in the metabolic measures (36). Thus, significance was considered at P<0.0003 to account for the testing of 54 independent metabolic measures and three sets of analyses conducted (main effects of statins, *PCSK9*, and differences in their effects). The significance of differences in the effect estimates was determined using the formula below and the corresponding p-values were derived from the normal distribution:

$$Z\_{diff}={(beta\_{statin}-beta\_{PCSK9})}/{\sqrt{(se\_{statin}^{2}-se\_{PCSK9}^{2})}}$$

To facilitate visualization of the results, we focused on 148 measures that cover all the metabolic pathways assayed; results for the remaining measures are shown in **Supplementary** **Figure 1** and **Supplementary** **Tables 4-6**. Statistical analyses were conducted using R3.2 (www.r-project.org).

# RESULTS

**Figure 1** provides an overview of the study design. Characteristics of the study populations are shown in **Table 1**. Characteristics of each of the eight cohorts used for the genetic analyses (N=72,185) are provided separately in **Supplementary** **Table 1**. The metabolic effects of statin treatment in PROSPER (pravastatin 40 mg/daily) and genetic inhibition of PCSK9 are compared in **Figure 2**. Overall, there was a high concordance of association of statin treatment and genetic inhibition of PCSK9 across the detailed metabolic profile (*R*2=0.88). Nonetheless, some discrepancies in effect sizes between statin treatment and *PCSK9* rs11591147 were evident, primarily for very-low-density lipoprotein (VLDL) lipids.

*Effects on lipoprotein lipids*

The specific effects of statin therapy and genetic inhibition of PCSK9 on lipid fractions and 14 lipoprotein subclasses are shown in **Figure 3**. Scaled to the same lowering of LDL-C, *PCSK9* rs11591147 displayed similar effects as statin therapy for total cholesterol and intermediate-density lipoprotein (IDL)-cholesterol, with no effect on high-density lipoprotein (HDL)-cholesterol. However, *PCSK9* rs11591147 had a weaker effect on lowering VLDL-cholesterol compared with statins (54% vs. 77%, relative to the lowering effect on LDL-C (%LDL-C); Phet=2x10-7). These results were substantiated by the pattern of reduction in lipoprotein subclass particles: while the effects were similar for lowering particle concentrations in all three (small, medium and large) LDL subclasses, the extent of lowering of small, medium-sized and large VLDL particle concentrationswas smaller for *PCSK9* rs11591147 compared with statin therapy. A similar discrepancy was observed for cholesterol concentrations within the six VLDL subclasses (**Figure 4**).

Both for statin therapy and genetic inhibition of PCSK9, the effects on triglyceride measures were modest compared to those observed for cholesterol levels in the same lipoprotein subfractions (**Figure 3**). The most pronounced lowering of triglycerides was seen for IDL and LDL particles. For the equivalent reductions in LDL-C, *PCSK9* rs11591147 displayed a weaker effect than statin therapy on lowering total plasma triglycerides (16%LDL-C vs. 37%LDL-C; Phet=3x10‑6). Similar differences were seen for VLDL and HDL triglycerides. Consistent with the observed discrepancies for lowering of medium and large VLDL particles, genetic inhibition ofPCSK9resulted in modestly larger VLDL size, whereas statin therapy had no effect on this measure. The effects on apolipoprotein concentrations were broadly similar, albeit a larger decrease was observed with statins for the ratio of apolipoprotein B to A-I.

## Effects on lipoprotein composition

In addition to affecting the absolute lipid concentrations, both statin therapy and genetic inhibition of PCSK9 had prominent effects on the relative abundance of lipid types (free and esterified cholesterol, triglycerides, and phospholipids) in differently sized lipoprotein subclasses (**Figure 4**). The most pronounced lipoprotein composition effects were observed within LDL subclasses, with substantial lowering in the relative abundance of cholesteryl esters in LDL particles, alongside increases in the abundance of free cholesterol and phospholipids. These effects were very similar for statin treatment compared with *PCSK9* rs11591147 for the equivalent reductions in LDL-C. Subtle discrepancies between statin and genetic inhibition of PCSK9 were observed, e.g., for the extent of lowering the fraction of free cholesterol in VLDL particles. The relative fraction of triglycerides in LDL and other apolipoprotein-B carrying particles increased similarly for both statins and *PCSK9* rs11591147,whereas statin therapy caused larger decreases in the relative abundance of triglycerides within HDL.

## Effects on fatty acids and polar metabolites

The effects of statin therapy and genetic inhibition ofPCSK9 on fatty acid concentrations and the balance of fatty acid ratios are shown in **Figure 5**. Absolute concentrations of all fatty acids were lowered, with the most pronounced lowering for concentrations of linoleic acid, an omega-6 fatty acid commonly bound to cholesteryl esters in LDL particles. For the same lowering of LDL-C, the effects of statins and *PCSK9* rs11591147were broadly similar, albeit with the lowering of total fatty acids being stronger in the case of statins (67%LDL-C vs. 50%LDL-C; Phet=2x10-4). The effects on the fatty acid ratios were generally modest, both for statin therapy and *PCSK9* rs11591147. A pronounced discrepancy between these was observed for the overall degree of fatty acid unsaturation (16%LDL-C reduction for *PCSK9* vs. 26%LDL-C increase for statin; Phet=4x10-20).

We further assessed the effects of statin therapy and *PCSK9* rs11591147 on polar metabolites and other metabolic measures quantified simultaneously in the metabolomics assay, including circulating amino acids, glycolysis metabolites, ketone bodies, and GlycA, a marker of chronic inflammation (37) (**Figure 6**). Statin therapy caused only minor effects on these metabolic measures; the strongest lowering effects were observed for GlycA (17%LDL-C) and isoleucine (7%LDL-C). The effects of *PCSK9* rs11591147 were also very close to null for these measures, including for glycolysis related metabolites and markers of insulin resistance. Of note, information on glucose, lactate, and pyruvate were not available in the PROSPER trial due to glycolysis progression after sample collection.

## Comparison to PREVEND-IT trial and Mendelian randomization

To replicate the detailed metabolic effects of statins observed in PROSPER, we compared them with recent results from the PREVEND-IT trial obtained using the same NMR metabolomics platform (13). PREVEND‑IT also examined the effects of pravastatin (40mg/day) with metabolomic changes assessed from baseline to 3-month for 195 individuals on treatment. The detailed metabolic effects of statin treatment were highly concordant between PROSPER and PREVEND-IT (*R*2=0.96; **Supplementary Figure 2**). When results were scaled to an equivalent lowering in LDL-C, 40 out of 44 significant discrepancies observed between effects of *PCSK9* rs11591147 compared to PROSPER were similar or somewhat larger in PREVEND-IT, including the deviations in VLDL lipids; the only exceptions were four measures of lipoprotein composition (fraction of free cholesterol in XXL-VLDL, triglyceride fraction in XL-VLDL, triglyceride fraction in L-HDL, and phospholipid fraction in S-LDL; **Supplementary Figure 1**).

We further compared the metabolic effects of *PCSK9* rs11591147 to those caused by rs12916­ in the *HMGCR* gene, hereby using the genetic variants to effectively act as two naturally occurring trials inthe same study population.Theoverall pattern of metabolic effects was highly similar for *PCSK9* rs11591147 and *HMGCR* rs12916 (*R*2=0.92; **Supplementary Figure 3A**). Nonetheless, scaled to the equivalent LDL-C reductions, similar deviations were observed for VLDL lipids as when comparing *PCSK9* rs11591147 to the statin trial results (**Supplementary Figure 4**).Specifically, the lowering effect of *HMGCR* rs12916-T on particle concentrations of all VLDL subclasses was more similar to the effects of statin treatment than to those of *PCSK9* rs11591147-T, except in the case of very small VLDL. Differences were also observed for cholesterol and triglyceride concentrations in VLDL subclasses, whereas the lowering of total and saturated fatty acids was similar for the *HMGCR* and *PCSK9* variants. However, power to detect statistical differences on individual measures was modest, due to the much weaker LDL-C lowering effect of *HMGCR* rs12916. Finally, the overall pattern of metabolic effects of statin therapy in PROSPER was highly concordant to effects of *HMGCR* rs12916 (*R*2=0.95; **Supplementary Figure 3B**), signifying pharmacological and genetic inhibition of HMG-CoA reductase, respectively.

In sensitivity analyses, the pattern of metabolic effects from *PCSK9* rs11591147 was consistent across the cohorts (**Supplementary Figure 5**). We also observed similar detailed patterns of metabolic effects as for rs11591147 when examining other genetic variants in *PCSK9* that have previously been used in Mendelian randomization studies (11,29) (**Supplementary Figure 6**). Results for all the 228 metabolic measures quantified are illustrated in **Supplementary Figures 1 and 4**. Metabolic effects in absolute concentration units are listed in **Supplementary Table 3**. The percentage differences in lipid and metabolite concentrations in the PROSPER statin trial are shown in **Supplementary Figure 7.** Effect estimates for all analyses are tabulated in **Supplementary Tables 4–6**.

# DISCUSSION

This study elucidates the comprehensive metabolic effects associated with statin therapy and PCSK9 inhibition. The results demonstrate that, as compared to statin therapy, genetic inhibition of PCSK9 yields comparable changes across many different markers of lipid metabolism when scaled to the equivalent lowering of LDL-C. However, our results also suggest that PCSK9 inhibitors may be somewhat less efficacious at lowering VLDL particles. This could potentially contribute to subtle differences in potency for lowering cardiovascular disease for the equivalent reductions in LDL-C (6), since recent evidence suggests that VLDL-cholesterol and other triglyceride-rich lipoprotein measures may causally contribute to the development of coronary heart disease independent of LDL-C (38-40). Moreover, trial data suggest that VLDL-cholesterol is a stronger predictor of cardiovascular event risk than LDL-C among patients on statin therapy (41,42).

Statins and PCSK9 inhibitors both lower circulating LDL-C levels via upregulation of LDL receptors on cell surfaces. Consistent with this shared mechanism for clearance of LDL particles, we found that statins and genetic inhibition of PCSK9 caused a highly consistent pattern of change across the detailed metabolic profile. The metabolomic profiling of the PROSPER trial corroborates previous studies with detailed measurements of metabolic effects of statin therapy, both as assessed in longitudinal cohorts and in a small randomized trial (12,13). By profiling a large number of individuals from multiple cohorts, our results also validate and extend previous studies examining the detailed metabolic effects of *PCSK9* rs11591147 (14,15). Importantly, in relation to assessment of potential side-effects of PCSK9 inhibition, we did not observe effects on amino acids or other non-lipid metabolites, many of which are associated with risk of incident diabetes and cardiovascular events (32,43,44). Our results on the pattern of lowering VLDL particles due to genetic inhibition of PCSK9 are consistent with two small trials assessing the effects of the PCSK9 inhibitors alirocumab and evolocumab on lipoprotein particle concentrations; both trials showed substantial reductions in small and medium-sized VLDL particles, while the particle concentration of the large VLDL fraction was not affected (16,17). Similar results were also found in a small PCSK9-inhibitor trial using separation of VLDL subfractions and other lipid measures by ultracentrifugation, which also corroborate our results on a stronger effect on lowering of VLDL-cholesterol as compared to total plasma triglycerides (18). However, differences in assay methods complicate direct comparison of these trials to our results. Overall, these results provide orthogonal evidence for diverse lipoprotein lipid alterations by PCSK9 inhibitors, coherent with the comprehensive metabolic effects of statins.

Currently licensed PCSK9 inhibitors are given either instead of statins – when there is strong evidence of statin intolerance in those with familial hypercholesterolemia – or in addition to maximally tolerated statins in patients with existing vascular disease (45). Such treatment with PCSK9 inhibitors has been shown to be more efficacious in lowering LDL-C than the most potent statins (4-6,8). Mendelian randomization studies comparing *PCSK9* and *HMGCR* gene scores on cardiovascular outcomes have indicated nearly identical protective effects for equivalent reductions in LDL-C (11,46). However, when scaling the metabolic effects to an equivalent lowering in LDL-C, the results of the present study indicate subtle differences on multiple lipoprotein lipid measures. The most notable discrepancy was for VLDL lipids, suggesting weaker potency of PCSK9 inhibitors in clearance of these triglyceride-rich lipoproteins as compared with statins. These findings are supported by a recent study providing evidence that statins, but not PCSK9 inhibitors, improve triglyceride-rich lipoprotein metabolism after an oral fat load in normolipidemic men (47). The causal consequences of these differences in medium-sized and large VLDL particles, that are rich in triglycerides, remain unclear and warrant further investigation; whereas IDL and the smallest VLDL particles can penetrate the arterial wall to cause atherosclerosis, it is commonly perceived not be to the case for larger VLDL particles (38,48). We also observed a difference in lowering of VLDL-cholesterol levels; the cholesterol concentrations of VLDL particles are strongly associated with risk of myocardial infarction (44) and some studies have suggested that VLDL-cholesterol could underpin the link between triglycerides and cardiovascular risk (38,41). If these VLDL particles do play a causal role in vascular disease, the discrepancy between statin therapy and PCSK9 inhibition could translate into slightly more potent cardiovascular risk reduction for the same LDL-C lowering for statins as compared with PCSK9 inhibition. We acknowledge that the present comparison of detailed metabolic effects of statin therapy and PCSK9 inhibition does not directly inform on the cardiovascular benefits of anti-PCSK9 therapies above current optimal care, but potentially in keeping with our findings, the cardiovascular outcome trials on PCSK9 inhibition have demonstrated slightly weaker cardiovascular event lowering compared to meta-analysis of statin trials per mmol/L reduction in LDL-C (6). While potential explanations for this discrepancy include the short trial duration and choice of primary end-point, other explanations, such as differences in anti-inflammatory effects, have also been suggested (11,49). Our results provide an additional hypothesis for exploration: the apparent weaker cardioprotective effects of PCSK9 inhibitors compared to statins per unit reduction in LDL-C may be due to weaker reductions in VLDL lipid concentrations by PCSK9 inhibition. This hypothesis warrants further investigation, including elucidation of the causal role of triglyceride-rich VLDL particles in tandem with further examinations of the detailed lipid effect of PCSK9 inhibitors.

Strengths and limitations of our study warrant consideration. The lack of NMR metabolomics data for a PCSK9 inhibition trial motivated the use of a loss-of-function variant in *PCSK9* as a proxy for the anticipated therapeutic effects. The close match in the detailed metabolic effects of statin therapy and *HMGCR* observed in this study substantiates the validity of using genetic variants to mimic lipid-lowering effects in randomized trial settings. While we note that the metabolic profile of other statins may differ to that of pravastatin, the similarity between *HMGCR* and statin therapy we identified provides reassurances about the generalizability of our findings to other statin types. To robustly assess the metabolic effects of genetic inhibition of PCSK9, we had more than five times the sample size of prior studies examining *PCSK9* rs11591147 on lipoprotein subclass profiles (14,15). Despite the large sample size, we had limited power to detect effects on glycolysis-related metabolites due to pre-analytical effects causing depletion of glucose levels in the blood samples. Notwithstanding the increased risk for type 2 diabetes linked with *PCSK9* rs11591147-T, our results indicating minute effects on glycolysis traits are in line with larger studies reporting null effects on fasting glucose for this SNP. The divergency in VLDL lipid lowering effects between statins and genetic inhibition of *PCSK9* could potentially be attributable to differences in the clinical characteristics of the older, high-risk patients of the PROSPER trial as compared to the younger cohort participants included in the genetic analyses. However, similar VLDL lowering effects due to pravastatin as observed in here PROSPER were recently reported in PREVEND IT (13) with younger and lower-risk trial participants (Figure S1). The differences in VLDL effects were also recapitulated when directly comparing the effects of genetic inhibition of PCSK9 to that of HMGCR in the same study population (Figure S4), providing reassurance that the observed VLDL differences are primarily due to the molecular mechanisms. Furthermore, the scaling of results to the LDL-C lowering magnitude enables comparison of the metabolic effects regardless the possible differences in the absolute lipid levels between the study populations. A strength of the metabolomics platform used is the ability to profile lipoprotein subclasses and their lipid composition at high-throughput, however we acknowledge that other assays may provide even deeper characterization of lipid metabolism and non-lipid pathways to further clarify the molecular effects of lipid-lowering therapies (50).

In conclusion, we found highly similar metabolic effects of statin therapy and genetic inhibition of PCSK9 across a comprehensive profile of lipids, lipoprotein subclasses, fatty acids, and polar metabolites. The detailed profiling of lipoprotein subclasses revealed weaker effects of PCSK9 inhibition on VLDL particles and their cholesterol concentrations as compared with statins, when scaled to an equivalent lowering of LDL-C. If some of these VLDL lipids have independent causal effects on cardiovascular risk, this could contribute to subtle differences in cardiovascular event reduction between statins and PCSK9 inhibitors. More broadly, these results exemplify the utility of large-scale metabolomics in combination with randomized trials and genetics to uncover potential molecular differences between related therapeutics.

**References**

1. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R. Interpretation of the evidence for the efficacy and safety of statin therapy. *Lancet.* 2016; 388: 2532-2561.

2. Ridker PM. LDL cholesterol: controversies and future therapeutic directions. *Lancet.* 2014; 384: 607-617.

3. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet.* 2012; 380: 581-590.

4. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. *N Engl J Med.* 2015; 372: 1500-1509.

5. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ, ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. *N Engl J Med.* 2015; 372: 1489-1499.

6. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. *N Engl J Med.* 2017; 376:1713-1722.

7. Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC, SPIRE Cardiovascular Outcome Investigators. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. *N Engl J Med.* 2017; 376: 1527-1539.

8. Ference BA, Cannon CP, Landmesser U, Luscher TF, Catapano AL, Ray KK. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. *Eur Heart J.* 2017; ehx450, https://doi.org/10.1093/eurheartj/ehx450.

9. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? *Int J Epidemiol.* 2003; 32: 1-22.

10. Cohen JC, Boerwinkle E, Mosley TH,Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. *N Engl J Med.* 2006; 354: 1264-1272.

11. Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, Voros S, Giugliano RP, Davey Smith G, Fazio S, Sabatine MS. Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. *N Engl J Med.* 2016; 375: 2144-2153.

12. Würtz P, Wang Q, Soininen P, Kangas AJ, Fatemifar G, Tynkkynen T, Tiainen M, Perola M, Tillin T, Hughes AD, Mantyselka P, Kahonen M, Lehtimaki T, Sattar N, Hingorani AD, Casas JP, Salomaa V, Kivimaki M, Jarvelin MR, Davey Smith G, Vanhala M, Lawlor DA, Raitakari OT, Chaturvedi N, Kettunen J, Ala-Korpela M. Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase. *J Am Coll Cardiol.* 2016; 67: 1200-1210.

13. Kofink D, Eppinga RN, van Gilst WH, Bakker SJL, Dullaart RPF, van der Harst P, Asselbergs FW. Statin Effects on Metabolic Profiles: Data From the PREVEND IT (Prevention of Renal and Vascular End-stage Disease Intervention Trial). *Circ Cardiovasc Genet.* 2017; 10:e001759.

14. Würtz P, Kangas AJ, Soininen P, Lehtimäki T, Kähönen M, Viikari JS, Raitakari OT, Järvelin M, Davey Smith G, Ala-Korpela M. Lipoprotein subclass profiling reveals pleiotropy in the genetic variants of lipid risk factors for coronary heart disease: a note on Mendelian randomization studies. *J Am Coll Cardiol.* 2013; 62: 1906-1908.

15. Verbeek R, Boyer M, Boekholdt SM, Hovingh GK, Kastelein JJ, Wareham N, Khaw KT, Arsenault BJ. Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopy-Brief Report. *Arterioscler Thromb Vasc Biol.* 2017; 37: 43-48.

16. Koren MJ, Kereiakes D, Pourfarzib R, Winegar D, Banerjee P, Hamon S, Hanotin C, McKenney JM. Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy. *J Am Heart Assoc.* 2015; 4: 10.1161/JAHA.115.002224.

17. Toth PP, Sattar N, Blom DJ, Martin SS, Jones SR, Monsalvo ML, Elliott M, Davis M, Somaratne R, Preiss D. Effect of Evolocumab on Lipoprotein Particles. *Am J Cardiol.* 2018; 121: 308-314.

18. Hilvo M, Simolin H, Metso J, Ruuth M, Oorni K, Jauhiainen M, Laaksonen R, Baruch A. PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions. *Atherosclerosis.* 2018; 269: 159-165.

19. Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjaerg-Hansen A. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. *J Am Coll Cardiol.* 2010; 55: 2833-2842.

20. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey G, Westendorp RG. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet.* 2002; 360: 1623-1630.

21. Di Angelantonio E, Thompson SG, Kaptoge S, Moore C, Walker M, Armitage J, Ouwehand WH, Roberts DJ, Danesh J, INTERVAL Trial Group. Efficiency and safety of varying the frequency of whole blood donation (INTERVAL): a randomised trial of 45 000 donors. *Lancet.* 2017; 390: 2360-2371.

22. Fraser A, Macdonald-Wallis C, Tilling K, Boyd A, Golding J, Davey Smith G, Henderson J, Macleod J, Molloy L, Ness A, Ring S, Nelson SM, Lawlor DA. Cohort Profile: the Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. *Int J Epidemiol.* 2013; 42: 97-110.

23. Boyd A, Golding J, Macleod J, Lawlor DA, Fraser A, Henderson J, Molloy L, Ness A, Ring S, Davey Smith G. Cohort Profile: the 'children of the 90s'--the index offspring of the Avon Longitudinal Study of Parents and Children. *Int J Epidemiol.* 2013; 42: 111-127.

24. Borodulin K, Tolonen H, Jousilahti P, Jula A, Juolevi A, Koskinen S, Kuulasmaa K, Laatikainen T, Männistö S, Peltonen M, Perola M, Puska P, Salomaa V, Sundvall J, Virtanen SM, Vartiainen E. Cohort Profile: The National FINRISK Study. *Int J Epidemiol.* 2017; 47, 696–696i.

25. Sabatti C, Service SK, Hartikainen AL, Pouta A, Ripatti S, Brodsky J, Jones CG, Zaitlen NA, Varilo T, Kaakinen M, Sovio U, Ruokonen A, Laitinen J, Jakkula E, Coin L, Hoggart C, Collins A, Turunen H, Gabriel S, Elliot P, McCarthy MI, Daly MJ, Jarvelin MR, Freimer NB, Peltonen L. Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. *Nat Genet.* 2009; 41: 35-46.

26. Kantomaa MT, Stamatakis E, Kankaanpää A, Kaakinen M, Rodriguez A, Taanila A, Ahonen T, Järvelin M, Tammelin T. Physical activity and obesity mediate the association between childhood motor function and adolescents' academic achievement. *Proc Natl Acad Sci U S A.* 2013; 110: 1917-1922.

27. Chen Z, Chen J, Collins R, Guo Y, Peto R, Wu F, Li L. China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up. *Int J Epidemiol.* 2011; 40: 1652-1666.

28. Delles C, Rankin NJ, Boachie C, McConnachie A, Ford I, Kangas A, Soininen P, Trompet S, Mooijaart SP, Jukema JW, Zannad F, Ala-Korpela M, Salomaa V, Havulinna AS, Welsh P, Würtz P, Sattar N. Nuclear magnetic resonance-based metabolomics identifies phenylalanine as a novel predictor of incident heart failure hospitalisation: results from PROSPER and FINRISK 1997. *Eur J Heart Fail.* 2018; 20:663-673.

29. Schmidt AF, Swerdlow DI, Holmes MV, Patel RS, Fairhurst-Hunter Z, Lyall DM, Hartwig FP, Horta BL, Hypponen E, Power C, Moldovan M, van Iperen E, Hovingh GK, Demuth I, Norman K, Steinhagen-Thiessen E, Demuth J, Bertram L, Liu T, Coassin S, Willeit J, Kiechl S, Willeit K, Mason D, Wright J, Morris R, Wanamethee G, Whincup P, Ben-Shlomo Y, McLachlan S, Price JF, Kivimaki M, Welch C, Sanchez-Galvez A, Marques-Vidal P, Nicolaides A, Panayiotou AG, Onland-Moret NC, van der Schouw, Y T, Matullo G, Fiorito G, Guarrera S, Sacerdote C, Wareham NJ, Langenberg C, Scott R, Luan J, Bobak M, Malyutina S, Pajak A, Kubinova R, Tamosiunas A, Pikhart H, Husemoen LL, Grarup N, Pedersen O, Hansen T, Linneberg A, Simonsen KS, Cooper J, Humphries SE, Brilliant M, Kitchner T, Hakonarson H, Carrell DS, McCarty CA, Kirchner HL, Larson EB, Crosslin DR, de Andrade M, Roden DM, Denny JC, Carty C, Hancock S, Attia J, Holliday E, O'Donnell M, Yusuf S, Chong M, Pare G, van der Harst P, Said MA, Eppinga RN, Verweij N, Snieder H, LifeLines Cohort study group, Christen T, Mook-Kanamori DO, Gustafsson S, Lind L, Ingelsson E, Pazoki R, Franco O, Hofman A, Uitterlinden A, Dehghan A, Teumer A, Baumeister S, Dorr M, Lerch MM, Volker U, Volzke H, Ward J, Pell JP, Smith DJ, Meade T, Maitland-van der Zee, A H, Baranova EV, Young R, Ford I, Campbell A, Padmanabhan S, Bots ML, Grobbee DE, Froguel P, Thuillier D, Balkau B, Bonnefond A, Cariou B, Smart M, Bao Y, Kumari M, Mahajan A, Ridker PM, Chasman DI, Reiner AP, Lange LA, Ritchie MD, Asselbergs FW, Casas JP, Keating BJ, Preiss D, Hingorani AD, UCLEB consortium, Sattar N. PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. *Lancet Diabetes Endocrinol.* 2017; 5: 97-105.

30. Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JEL, Shah T, Sofat R, Stender S, Johnson PCD, Scott RA, Leusink M, Verweij N, Sharp SJ, Guo Y, Giambartolomei C, Chung C, Peasey A, Amuzu A, Li K, Palmen J, Howard P, Cooper JA, Drenos F, Li YR, Lowe G, Gallacher J, Stewart MCW, Tzoulaki I, Buxbaum SG, A, Daphne L van der, Forouhi NG, Onland-Moret NC, Schouw, Yvonne T van der, Schnabel RB, Hubacek JA, Kubinova R, Baceviciene M, Tamosiunas A, Pajak A, Topor-Madry R, Stepaniak U, Malyutina S, Baldassarre D, Sennblad B, Tremoli E, Faire Ud, Veglia F, Ford I, Jukema JW, Westendorp RGJ, Borst GJd, Jong PAd, Algra A, Spiering W, Zee, Anke H Maitland-van der, Klungel OH, Boer Ad, Doevendans PA, Eaton CB, Robinson JG, Duggan D, Kjekshus J, Downs JR, Gotto AM, Keech AC, Marchioli R, Tognoni G, Sever PS, Poulter NR, Waters DD, Pedersen TR, Amarenco P, Nakamura H, McMurray JJV, Lewsey JD, Chasman DI, Ridker PM, Maggioni AP, Tavazzi L, Ray KK, Seshasai SRK, Manson JE, Price JF, Whincup PH, Morris RW, Lawlor DA, Smith GD, Ben-Shlomo Y, Schreiner PJ, Fornage M, Siscovick DS, Cushman M, Kumari M, Wareham NJ, Verschuren WMM, Redline S, Patel SR, Whittaker JC, Hamsten A, Delaney JA, Dale C, Gaunt TR, Wong A, Kuh D, Hardy R, Kathiresan S, Castillo BA, Harst Pvd, Brunner EJ, Tybjaerg-Hansen A, Marmot MG, Krauss RM, Tsai M, Coresh J, Hoogeveen RC, Psaty BM, Lange LA, Hakonarson H, Dudbridge F, Humphries SE, Talmud PJ, Kivimäki M, Timpson NJ, Langenberg C, Asselbergs FW, Voevoda M, Bobak M, Pikhart H, Wilson JG, Reiner AP, Keating BJ, Hingorani AD, Sattar N. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. *Lancet.* 2015; 385: 351-361.

31. Soininen P, Kangas AJ, Würtz P, Suna T, Ala-Korpela M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. *Circ Cardiovasc Genet.* 2015; 8: 192-206.

32. Würtz P, Havulinna AS, Soininen P, Tynkkynen T, Prieto-Merino D, Tillin T, Ghorbani A, Artati A, Wang Q, Tiainen M, Kangas AJ, Kettunen J, Kaikkonen J, Mikkilä V, Jula A, Kähönen M, Lehtimäki T, Lawlor DA, Gaunt TR, Hughes AD, Sattar N, Illig T, Adamski J, Wang TJ, Perola M, Ripatti S, Vasan RS, Raitakari OT, Gerszten RE, Casas J, Chaturvedi N, Ala-Korpela M, Salomaa V. Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. *Circulation.* 2015; 131: 774-785.

33. Kettunen J, Tukiainen T, Sarin AP, Ortega-Alonso A, Tikkanen E, Lyytikainen LP, Kangas AJ, Soininen P, Würtz P, Silander K, Dick DM, Rose RJ, Savolainen MJ, Viikari J, Kahonen M, Lehtimaki T, Pietilainen KH, Inouye M, McCarthy MI, Jula A, Eriksson J, Raitakari OT, Salomaa V, Kaprio J, Jarvelin MR, Peltonen L, Perola M, Freimer NB, Ala-Korpela M, Palotie A, Ripatti S. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. *Nat Genet.* 2012; 44: 269-276.

34. Kettunen J, Demirkan A, Würtz P, Draisma HH, Haller T, Rawal R, Vaarhorst A, Kangas AJ, Lyytikainen LP, Pirinen M, Pool R, Sarin AP, Soininen P, Tukiainen T, Wang Q, Tiainen M, Tynkkynen T, Amin N, Zeller T, Beekman M, Deelen J, van Dijk KW, Esko T, Hottenga JJ, van Leeuwen EM, Lehtimaki T, Mihailov E, Rose RJ, de Craen AJ, Gieger C, Kahonen M, Perola M, Blankenberg S, Savolainen MJ, Verhoeven A, Viikari J, Willemsen G, Boomsma DI, van Duijn CM, Eriksson J, Jula A, Jarvelin MR, Kaprio J, Metspalu A, Raitakari O, Salomaa V, Slagboom PE, Waldenberger M, Ripatti S, Ala-Korpela M. Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. *Nat Commun.* 2016; 7: 11122.

35. Würtz P, Kangas AJ, Soininen P, Lawlor DA, Davey Smith G, Ala-Korpela M. Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology: A Primer on -Omic Technologies. *Am J Epidemiol.* 2017; 186: 1084-1096.

36. Kujala UM, Makinen VP, Heinonen I, Soininen P, Kangas AJ, Leskinen TH, Rahkila P, Würtz P, Kovanen V, Cheng S, Sipila S, Hirvensalo M, Telama R, Tammelin T, Savolainen MJ, Pouta A, O'Reilly PF, Mantyselka P, Viikari J, Kahonen M, Lehtimaki T, Elliott P, Vanhala MJ, Raitakari OT, Jarvelin MR, Kaprio J, Kainulainen H, Ala-Korpela M. Long-term leisure-time physical activity and serum metabolome. *Circulation.* 2013; 127: 340-348.

37. Ritchie SC, Würtz P, Nath AP, Abraham G, Havulinna AS, Fearnley LG, Sarin AP, Kangas AJ, Soininen P, Aalto K, Seppala I, Raitoharju E, Salmi M, Maksimow M, Mannisto S, Kahonen M, Juonala M, Ripatti S, Lehtimaki T, Jalkanen S, Perola M, Raitakari O, Salomaa V, Ala-Korpela M, Kettunen J, Inouye M. The Biomarker GlycA Is Associated with Chronic Inflammation and Predicts Long-Term Risk of Severe Infection. *Cell Syst.* 2015; 1: 293-301.

38. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. *Lancet.* 2014; 384: 626-635.

39. White J, Swerdlow DI, Preiss D, Fairhurst-Hunter Z, Keating BJ, Asselbergs FW, Sattar N, Humphries SE, Hingorani AD, Holmes MV. Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. *JAMA Cardiol.* 2016; 1: 692-699.

40. Dewey FE, Gusarova V, Dunbar RL, O’Dushlaine C, Schurmann C, Gottesman O, McCarthy S, Van Hout CV, Bruse S, Dansky HM, Leader JB, Murray MF, Ritchie MD, Kirchner HL, Habegger L, Lopez A, Penn J, Zhao A, Shao W, Stahl N, Murphy AJ, Hamon S, Bouzelmat A, Zhang R, Shumel B, Pordy R, Gipe D, Herman GA, Sheu WHH, Lee I, Liang K, Guo X, Rotter JI, Chen YI, Kraus WE, Shah SH, Damrauer S, Small A, Rader DJ, Wulff AB, Nordestgaard BG, Tybjærg-Hansen A, van den Hoek, Anita M, Princen HMG, Ledbetter DH, Carey DJ, Overton JD, Reid JG, Sasiela WJ, Banerjee P, Shuldiner AR, Borecki IB, Teslovich TM, Yancopoulos GD, Mellis SJ, Gromada J, Baras A. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. *N Engl J Med.* 2017*.* 2017; 377: 211-221.

41. Lawler PR, Akinkuolie AO, Harada P, Glynn RJ, Chasman DI, Ridker PM, Mora S. Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Very-Low-Density Lipoproteins. *J Am Heart Assoc.* 2017; 6: e007402. doi: 10.1161/JAHA.117.007402.

42. Lawler PR, Akinkuolie AO, Chu AY, Shah SH, Kraus WE, Craig D, Padmanabhan L, Glynn RJ, Ridker PM, Chasman DI, Mora S. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol. *J Am Heart Assoc.* 2017; 6: 10.1161/JAHA.117.005549.

43. Guasch-Ferre M, Hruby A, Toledo E, Clish CB, Martinez-Gonzalez MA, Salas-Salvado J, Hu FB. Metabolomics in Prediabetes and Diabetes: A Systematic Review and Meta-analysis. *Diabetes Care.* 2016; 39: 833-846.

44. Holmes MV, Millwood IY, Kartsonaki C, Hill MR, Bennett DA, Boxall R, Guo Y, Xu X, Bian Z, Hu R, Walters RG, Chen J, Ala-Korpela M, Parish S, Clarke RJ, Peto R, Collins R, Li L, Chen Z, China Kadoorie Biobank Collaborative Group. Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke. *J Am Coll Cardiol.* 2018; 71: 620-632.

45. Annemans L, Packard CJ, Briggs A, Ray KK. 'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. *Eur Heart J.* 2017; ehx710, https://doi.org/10.1093/eurheartj/ehx710.

46. Holmes MV, Smith GD. Dyslipidaemia: Revealing the effect of CETP inhibition in cardiovascular disease. *Nat Rev Cardiol.* 2017; 14: 635-636.

47. Chan DC, Watts GF, Somaratne R, Wasserman SM, Scott R, Barrett PHR. Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism. *Arterioscler Thromb Vasc Biol.* 2018; .

48. Öörni K, Posio P, Ala-Korpela M, Jauhiainen M, Kovanen PT. Sphingomyelinase induces aggregation and fusion of small very low-density lipoprotein and intermediate-density lipoprotein particles and increases their retention to human arterial proteoglycans. *Arterioscler Thromb Vasc Biol.* 2005; 25: 1678-1683.

49. Waters DD, Hsue PY. PCSK9 Inhibition to Reduce Cardiovascular Risk: Tempering Expectations. *Circ Res.* 2017; 120: 1537-1539.

50. Voora D, Shah SH. Pharmacometabolomics Meets Genetics: A "Natural" Clinical Trial of Statin Effects. *J Am Coll Cardiol.* 2016; 67: 1211-1213.

**Table 1. Baseline characteristics of participants in the PROSPER statin trial and cohorts for analyses of genetic inhibition of PCSK9.**

|  |  |  |
| --- | --- | --- |
| **Characteristics** | **PROSPER statin trial** | **Cohorts in analyses of genetic variants** |
| **Placebo** | **Pravastatin** |
| Number of individuals | 2,700 | 2,659 | 72,185 |
| Male (%) | 48.3 | 48.3 | 47.1 |
| Age (year) | 75.3 ± 3.4 | 75.4 ± 3.3 | 39.3 ± 5.3 |
| BMI (kg/m2) | 26.8 ± 4.3 | 26.8 ± 4.1 | 25.2 ± 4.4 |
| Triglycerides (mmol/L) | 1.5 ± 0.7 | 1.5 ± 0.7 | 1.2 ± 0.6 |
| Total cholesterol (mmol/L) | 5.7 ± 0.9 | 5.7 ± 0.9 | 4.5 ± 1.0 |
| HDL cholesterol (mmol/L) | 1.3 ± 0.3 | 1.3 ± 0.4 | 1.4 ± 0.4 |
| Friedewald LDL cholesterol (mmol/L) |  3.8 ± 0.8 | 3.8 ± 0.8  | 2.4 ± 0.8 |

Values are mean±SD.

\* Pooled results of eight cohorts from different geographical and ethnic backgrounds and age distributions; characteristics of each cohort are detailed in **Table S1**.

****

**Figure 1. Overview of the study design and statistical analyses.**



**Figure 2. Consistency of metabolic effects of statin treatment and *PCSK9* rs11591147-T.**

The effect size of each metabolic measure is given with 95% confidence intervals in gray vertical and horizontal error bars. Color coding for the metabolic measure indicates the P-value for heterogeneity between statin therapy and *PCSK9* rs11591147-T. *R*2 = 0.880 indicates goodness of fit (correlation squared). The red dashed line denotes the linear fit for the consistency of the metabolic effects (slope of this line = 0.879).

C: cholesterol; FA: fatty acids; HDL: high-density lipoprotein; IDL: intermediate-density lipoprotein; LDL: low-density lipoprotein; PL: phospholipids; PUFA: polyunsaturated fatty acids; TG: triglycerides; very-low-density lipoprotein. A full list of metabolite names is given in **Supplementary Table 2**.



**Figure 3. Effects of statin treatment and genetic inhibition of PCSK9 on lipoprotein and lipid levels.**

Differences in lipoprotein and lipid levels due to statin treatment were assessed in the PROSPER trial at 6‑month post randomization (black diamonds; n=5359 for which 2659 were on pravastatin 40mg/day). The corresponding effects of *PCSK9* rs11591147-T were assessed for n=72,185 by meta-analysis of eight cohorts (red circles). Error bars indicate 95% confidence intervals. Effect estimates are shown in SD-scaled concentration units (top axis) and relative to the lowering effect on LDL-C (bottom axis). The results for different lipid types within the 14 lipoprotein subclasses are shown in **Supplementary Figure 1**. Effects in absolute concentration units are listed in **Supplementary Table 3**.



**Figure 4. Effects of statin treatment and genetic inhibition of PCSK9 on lipoprotein composition.**

Differences in lipoprotein composition measures due to statin treatment were assessed 6-months post randomization in the PROSPER trial (black). The corresponding effects of *PCSK9* rs11591147-T were assessed for n=72,185 (red). Error bars indicate 95% confidence intervals. Results are shown in SD-scaled concentration units (top axis) and relative to the lowering effect on LDL-C (bottom axis).



**Figure 5. Effects of statin treatment and genetic inhibition of PCSK9 on fatty acids.**

Differences in fatty acid levels due to statin treatment were assessed 6-months post randomization in the PROSPER trial (black). The corresponding effects of *PCSK9* rs11591147-T were assessed for n=72,185. Error bars indicate 95% confidence intervals. Results are shown in SD-scaled concentration units (top axis) and relative to the lowering effect on LDL-C (bottom axis).



**Figure 6. Effects of statin treatment and genetic inhibition of PCSK9 on polar metabolites.**

Differences in metabolite levels due to statin treatmentwere assessed 6-month post randomization in the PROSPER trial (black). The corresponding effects of *PCSK9* rs11591147-T were assessed for n=72,185. Error bars indicate 95% confidence intervals. Glycine, glucose, lactate, pyruvate and glycerol measures were not available from PROSPER. Results are shown in SD-scaled concentration units (top axis) and relative to the lowering effect on LDL-C (bottom axis).

# AUTHORS

# Eeva Sliz1,2, MSc; Johannes Kettunen1,2,3, PhD; Michael V Holmes4,5,6,7, MD PhD; Clare Oliver Williams8,9, PhD; Charles Boachie10, PhD; Qin Wang1,2,3,11, PhD; PhD; Minna Männikkö12, PhD; Sylvain Sebert1,2,13, PhD; Robin Walters5, PhD; Kuang Lin5, PhD; Iona Y Millwood5, DPhil; Robert Clarke5, MD; Liming Li14,15 , MPH; Naomi Rankin16, PhD; Paul Welsh16, PhD; Christian Delles16, MD; J. Wouter Jukema17, MD PhD; Stella Trompet17,18, PhD; Ian Ford10, PhD; Markus Perola19,20,21, MD PhD; Veikko Salomaa19, MD PhD; Marjo-Riitta Järvelin1,2,22,23, MD PhD; Zhengming Chen5, DPhil; Debbie A Lawlor7,24, MD PhD; Mika Ala-Korpela1,2,3,7,11,24,25,26 PhD; John Danesh8,27,28, FMedSci; George Davey Smith7,24, DSc; Naveed Sattar16#, FMedSci; Adam Butterworth8,27,#, PhD; Peter Würtz29,30,#,\*, PhD

# 1. Center for Life Course Health Research, University of Oulu, Oulu, Finland

# 2. Biocenter Oulu, Oulu, Finland

# 3. Computational Medicine, Faculty of Medicine, University of Oulu, Finland

# 4. Medical Research Council Population Health Research Unit, University of Oxford, Oxford, UK

# 5. Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK

# 6. National Institute for Health Research, Oxford Biomedical Research Centre, Oxford University Hospital, Oxford, UK

# 7. Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, UK

# 8. MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom

# 9. Homerton College, University of Cambridge, Cambridge, UK

# 10. Robertson Centre for Biostatistics, Boyd Orr Building, University of Glasgow, Glasgow, UK

# 11. Systems Epidemiology, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia

# 12. Northern Finland Birth Cohorts, Faculty of Medicine, University of Oulu, Oulu, Finland

# 13. Department of Genomics of Complex Diseases, School of Public Health, Imperial College London, UK

# 14. Chinese Academy of Medical Sciences, 9 Dongdan San Tiao, Beijing, China

# 15. Department of Global Health, School of Public Health, Peking University, Beijing, China

# 16. Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK

# 17. Leiden University Medical Centre, Leiden, The Netherlands

# 18. Department of Internal Medicine, section of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands

# 19. National Institute for Health and Welfare, Helsinki, Finland

# 20. Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland

# 21. University of Tartu, Estonian Genome Center, Tartu, Estonia

# 22. Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment and Health, Imperial College London, London, UK

# 23. Unit of Primary Care, Oulu University Hospital, Oulu, Finland

# 24. Population Health Science, Bristol Medical School, University of Bristol, Bristol, UK

# 25. NMR Metabolomics Laboratory, School of Pharmacy, University of Eastern Finland, Kuopio, Finland

# 26. Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, The Alfred Hospital, Monash University, Melbourne, VIC, Australia

# 27. National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge, Cambridge, United Kingdom

# 28. Wellcome Trust Sanger Institute, Hinxton, United Kingdom

# 29. Diabetes and Obesity Research Program, University of Helsinki, Helsinki, Finland

# 30. Nightingale Health Ltd, Helsinki, Finland

# # joint senior authors.

**Conflict of Interest Disclosures:**

PW is employee and shareholder of Nightingale Health Ltd, a company offering NMR‑based metabolic profiling. JK reports stock options in Nightingale Health. The Clinical Trial Service Unit & Epidemiological Studies Unit (MVH, RW, KL, IM, RC, ZC) has received research grants from Abbott/ Solvay/Mylan, AstraZeneca, Bayer, GlaxoSmithKline, Merck, Novartis, Pfizer, Roche, and Schering. MVH has collaborated with Boehringer Ingelheim in research, and in accordance with the policy of the Clinical Trial Service Unit and Epidemiological Studies Unit (University of Oxford), did not accept any personal payment. DAL has received support from several government and charity health research funders and from Roche Diagnostics and Medtronic for research unrelated to that published here. NS has consulted for AstraZeneca, Bristol-Myers Squibb, Amgen, Sanofi, and Boehringer Ingelheim. ASB has received grants from Merck, Pfizer, Biogen, Bioverativ and AstraZeneca. VS has received a conference trip and an honorarium from Novo Nordisk. No other authors reported disclosures.

# Funding Sources:

This study was supported by the Academy of Finland (grant numbers 312476, 312477, 297338 and 307247), University of Oulu Graduate School, Strategic Research Funding from the University of Oulu, Finland, the Novo Nordisk Foundation (grant number NNF17OC0026062 and 15998), the Sigrid Juselius Foundation, and the UK Medical Research Council via the MRC University of Bristol Integrative Epidemiology Unit (MC\_UU\_12013/1 and MC\_UU\_12013/5). MVH works in a unit that receives funding from the UK Medical Research Council and is supported by a British Heart Foundation Intermediate Clinical Research Fellowship (FS/18/23/33512) and the National Institute for Health Research Oxford Biomedical Research Centre. QW was supported by a Novo Nordisk Foundation Postdoctoral Fellowship (grant number NNF17OC0027034). QW and MAK work at The Baker Institute that is supported in part by the Victorian Government’s Operational Infrastructure Support Program.

PROSPER metabolic profiling by NMR was supported by the European Federation of Pharmaceutical Industries Associations (EFPIA), Innovative Medicines Initiative Joint Undertaking, European Medical Information Framework (EMIF) grant number 115372 and the European Commission under the Health Cooperation Work Programme of the 7th Framework Programme (Grant number 305507) “Heart ‘omics’ in AGEing” (HOMAGE).

The INTERVAL academic coordinating centre receives core support from the UK Medical Research Council (G0800270), the BHF (SP/09/002), the NIHR, and Cambridge Biomedical Research Centre, as well as grants from the European Research Council (268834), the European Commission Framework Programme 7 (HEALTH-F2-2012-279233), Merck, and Pfizer. The INTERVAL study is funded by NHSBT (11-01-GEN) and has been supported by the NIHR-BTRU in Donor Health and Genomics (NIHR BTRU-2014- 10024) at the University of Cambridge in partnership with NHSBT.

ALSPAC receives core support from the UK Medical Research Council and Wellcome Trust (Grant: 102215/2/13/2) and the University of Bristol. Data collection and metabolic profiling in the ALSPAC mother’s study were obtained from British Heart Foundation (SP/07/008/24066) and the Wellcome Trust (WT092830M). Genetic data in the ALSPAC mothers was obtained through funding from the Wellcome Trust (WT088806). ALSPAC offspring genetic data was obtained with support from 23andMe.

The FINRISK studies have received financial support related to the present study from the he National Institute for Health and Welfare, the Academy of Finland (139635), and the Finnish Foundation for Cardiovascular Research (to V.S).

NFBC1966 received financial support from University of Oulu Grant no. 65354, Oulu University Hospital Grant no. 2/97, 8/97, Ministry of Health and Social Affairs Grant no. 23/251/97, 160/97, 190/97, National Institute for Health and Welfare, Helsinki Grant no. 54121, Regional Institute of Occupational Health, Oulu, Finland Grant no. 50621, 54231. NFBC1986 received financial support from EU QLG1-CT-2000-01643 (EUROBLCS) Grant no. E51560, NorFA Grant no. 731, 20056, 30167, USA / NIHH 2000 G DF682 Grant no. 50945. MRJ and SS received financial by the European commission under grant agreement H2020-633595 for DynaHEALTH and H2020-733206 for LifeCycle; the academy of Finland EGEA-project (GA-285547) and the Biocenter Oulu.

The China Kadoorie Biobank baseline survey and first re-survey was supported by the Kadoorie Charitable Foundation in Hong Kong. Long-term follow-up has been supported by the UK Wellcome Trust (202922/Z/16/Z, 088158/Z/09/Z, 104085/Z/14/Z), National Key Research and Development Program of China (2016YFC0900500, 2016YFC0900501, 2016YFC0900504), Chinese Ministry of Science and Technology (2011BAI09B01), and National Natural Science Foundation of China (Grants No. 81390540, No. 81390541, No. 81390544). NMR metabolomics was supported by the BHF Centre of Research Excellence, Oxford (RE/13/1/30181). The British Heart Foundation, UK Medical Research Council and Cancer Research UK provide core funding to the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) at the University of Oxford. MVH was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre. DNA extraction and genotyping was performed by BGI, Shenzhen, China.

The funders of the individual study cohorts had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The views expressed in this paper are those of the authors and not necessarily any funding body.

# SUPPLEMENTARY MATERIAL

Supplementary Methods

Table S1. Clinical characteristics of the eight cohorts included in the genetic analyses of *PCSK9* rs11591147 and *HMGCR* rs12916

Table S2. Metabolite mean (SD) concentrations in PROSPER and cohorts used for genetic analyses

Figure S1. Effects of statin treatment and genetic inhibition of PCSK9 on 228 metabolic traits.

Figure S2. Consistency of metabolic effects of pravastatin 40 mg/day in PROSPER vs. PREVEND IT trials.

Figure S3. Consistency of metabolic effects of *HMGCR* rs12916-T vs. (A) *PCSK9* rs11591147-T, and (B) statin therapy in the PROSPER trial.

Figure S4. Metabolomic effects of statin treatment, *HMGCR* rs12916-T and *PCSK9* rs11591147-T.

Figure S5. Consistency of metabolomic effects of *PCSK9* rs11591147-T across the cohorts on 228 metabolic traits.

Figure S6. Consistency of metabolic effects of the main instrument *PCSK9* rs11591147-T with other *PCSK9* variants.

Figure S7. Percentage differences in metabolite concentrations in pravastatin versus placebo group in PROSPER trial.

*Spreadsheet file:*

Table S3. Main results in absolute concentration units.

Table S4. Metabolic effects of statin therapy in the PROSPER trial in SD-units.

Table S5. Metabolic effects of *PCSK9* rs11591147-T in SD units.

Table S6. Metabolic effects of *HMGCR* rs12916-T in SD-units.